Ssgj-705
Receptor, ErbB-2
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Receptor, ErbB-2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Ssgj-705 is also rated in:
Locally Advanced (Unresectable) or Metastatic Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →